Who are the top shareholders of the Link Pharma Chem?

The top shareholders of Link Pharma Chem include Rishikesh Satishbhai Thakur with 18.95%, followed by Gurudev Marketing Pvt. Ltd. at 5.76%, and individual investors holding 37.17%. There are no pledged promoter holdings, minimal mutual fund involvement, and no foreign institutional investors.

The top shareholders of Link Pharma Chem include the promoters, with Rishikesh Satishbhai Thakur holding the largest share at 18.95%. The company has no pledged promoter holdings. In terms of public shareholders, Gurudev Marketing Pvt. Ltd. is the highest public shareholder with a stake of 5.76%. Additionally, individual investors collectively hold 37.17% of the shares. Mutual funds have a minimal presence, with only one scheme holding 0.02%, and there are currently no foreign institutional investors (FIIs) involved.

Who are in the management team of Link Pharma Chem?

As of March 2023, the management team of Link Pharma Chem includes S G Thakur (Chairman & Wholetime Director), Rishikesh S. Thakur (Managing Director), and independent directors S B Dhatrak, Devang U Shah, and Rachna Ghai. They are responsible for the company's governance and strategic direction.

As of March 2023, the management team of Link Pharma Chem includes the following individuals:<BR><BR>1. S G Thakur - Chairman & Wholetime Director<BR>2. Rishikesh S. Thakur - Managing Director<BR>3. S B Dhatrak - Independent Director<BR>4. Devang U Shah - Independent Director<BR>5. Rachna Ghai - Independent Director<BR><BR>These members play key roles in the governance and strategic direction of the company.

Has Link Pharma Chem declared dividend?

No Dividend History Available

Who are the peers of the Link Pharma Chem?

Link Pharma Chem's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Vivid Global, Kuwer Industries, Bhagawati Oxygen, and Lime Chemicals. In terms of management risk, GHCL and Chemplast Sanmar are excellent, while Link Pharma Chem has average risk; India Glycols leads in 1-year returns at 150.38%, with Link Pharma Chem at -10.37%.

Peers: The peers of Link Pharma Chem are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Vivid Global, Kuwer Industries, Bhagawati Oxygen, and Lime Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Chemplast Sanmar, while Average management risk is found at Tata Chemicals, India Glycols, and Link Pharma Chem. Below Average management risk is present at Fischer Medical, Vivid Global, Kuwer Industries, and Lime Chemicals, and Bhagawati Oxygen does not qualify. Growth is below average for Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Link Pharma Chem, Kuwer Industries, and Lime Chemicals, while Fischer Medical and Vivid Global also show average growth. Bhagawati Oxygen and Tulasee Bio-Eth. do not qualify for growth. Capital structure is excellent at GHCL, average at Tata Chemicals and Link Pharma Chem, and below average at Chemplast Sanmar, India Glycols, Fischer Medical, Vivid Global, Kuwer Industries, and Lime Chemicals, with Bhagawati Oxygen and Tulasee Bio-Eth. not qualifying.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.38%, while Lime Chemicals has the lowest at -37.18%. Link Pharma Chem's 1-year return of -10.37% is better than Lime Chemicals but worse than India Glycols. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Lime Chemicals, and Bhagawati Oxygen.

Is Link Pharma Chem overvalued or undervalued?

As of May 28, 2025, Link Pharma Chem is considered risky and overvalued with a negative PE ratio of -15.17 and a year-to-date return of -12.29%, significantly underperforming compared to its peers like Godrej Industries and the Sensex.

As of 28 May 2025, the valuation grade for Link Pharma Chem has moved from very attractive to risky. The company is currently assessed as overvalued, given its negative PE ratio of -15.17, an EV to EBITDA of 22.01, and a ROE of -7.51%. These ratios indicate significant financial distress and a lack of profitability, which is concerning for potential investors.<BR><BR>In comparison to its peers, Link Pharma Chem's valuation metrics starkly contrast with those of Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, indicating a more favorable market position. Additionally, Solar Industries is deemed very expensive with a PE ratio of 123.77, highlighting the disparity in valuation within the sector. Despite a recent uptick in stock price, Link Pharma Chem's year-to-date return of -12.29% significantly underperforms the Sensex's 5.66%, reinforcing the notion of its overvaluation.

What is the technical trend for Link Pharma Chem?

As of June 5, 2025, Link Pharma Chem's trend has shifted to bearish, supported by bearish indicators from moving averages and Bollinger Bands, despite some mixed signals from the MACD and KST.

As of 5 June 2025, the technical trend for Link Pharma Chem has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD indicates a bearish trend. Both the weekly and monthly Bollinger Bands confirm a bearish outlook. Daily moving averages are also bearish, reinforcing the negative sentiment. The KST shows a mildly bullish signal on the weekly chart, but is bearish on the monthly, indicating mixed signals. Overall, the lack of clear trends in Dow Theory further supports a bearish perspective.

What does Link Pharma Chem do?

Link Pharma Chem Ltd is a mid-sized chemical manufacturing company specializing in commodity chemicals, primarily thionil chloride. As of March 2025, it reported net sales of 64 Cr and a net loss of 4 Cr, with a market cap of INR 16 Cr.

Overview:<BR>Link Pharma Chem Ltd is a mid-size leading chemical manufacturing company operating in the commodity chemicals industry, categorized as a micro-cap.<BR><BR>History:<BR>The company was incorporated in 1986 and has undergone several capacity expansions, increasing its production of thionil chloride from 300 tpa to 2100 tpa by 1994. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 64 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -4 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 16 Cr (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.47 <BR>Return on Equity: -7.51% <BR>Price to Book: 1.14 <BR><BR>Contact Details:<BR>Address: 162, GIDC Ind Estate Nandesari Vadodara Gujarat : 391340 <BR>Tel: 91-0265-3065000/2840448/3093931 <BR>Email: linkpharmacs@gmail.com <BR>Website: http://www.linkpharmachem.co.in

How big is Link Pharma Chem?

As of 24th July, Link Pharma Chem Ltd has a market capitalization of 16.00 Cr and reported Net Sales of 25.44 Cr with a Net Profit loss of 1.03 Cr for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 13.71 Cr and Total Assets of 25.95 Cr.

As of 24th July, Link Pharma Chem Ltd has a market capitalization of 16.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 25.44 Cr. However, it experienced a loss of 1.03 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 13.71 Cr and Total Assets amounting to 25.95 Cr.

Are Link Pharma Chem latest results good or bad?

Link Pharma Chem's latest results are mixed; while profitability metrics have improved with record operating profit and earnings per share, net sales have declined by 21.03% year-on-year, raising concerns about future financial health.

Link Pharma Chem's latest results present a mixed picture. On one hand, the company has shown significant improvements in profitability metrics. The operating profit before depreciation, interest, and tax (PBDIT) reached Rs 0.64 crore, the highest in the last five quarters, and both profit before tax (PBT) and profit after tax (PAT) also peaked during this period. Additionally, earnings per share (EPS) increased to Rs 0.90, indicating better profitability for shareholders.<BR><BR>On the other hand, the company is facing challenges with net sales, which have declined by 21.03% year-on-year, totaling Rs 19.60 crore for the nine-month period. While there was a positive quarter-on-quarter growth in net sales of 21.09% compared to the previous quarter, the overall downward trend in sales could pose risks to the company's financial health moving forward.<BR><BR>In summary, while Link Pharma Chem has made strides in profitability, the significant drop in sales is a concern that could impact future performance.

When is the next results date for Link Pharma Chem?

Link Pharma Chem will announce its results on 13 November 2025.

Link Pharma Chem is scheduled to declare its results on 13 November 2025.

How has been the historical performance of Link Pharma Chem?

Link Pharma Chem has experienced a significant decline in net sales and profitability, with losses reported in the most recent fiscal year. Net sales dropped from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, and the company reported a profit after tax loss of -1.03 Cr in March 2025.

Answer:<BR>The historical performance of Link Pharma Chem shows a declining trend in net sales and profitability over the past few years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Link Pharma Chem's net sales have decreased from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, reflecting a significant decline. The total operating income followed a similar trend, dropping from 53.56 Cr in March 2022 to 25.43 Cr in March 2025. The company's total expenditure also decreased, but not as sharply, leading to operating profits that turned negative in March 2024 and remained low at 0.31 Cr in March 2025. Profit before tax has been negative since March 2024, with a loss of 1.40 Cr reported in March 2025. Consequently, the profit after tax also showed losses, amounting to -1.03 Cr in March 2025. The company's total assets decreased from 32.46 Cr in March 2023 to 23.06 Cr in March 2025, while total liabilities also fell from 25.95 Cr to 23.06 Cr in the same period. Cash flow from operating activities was positive at 2.00 Cr in March 2025, but the overall cash position remained stagnant, with no cash inflow or outflow reported. Overall, Link Pharma Chem has faced significant challenges, leading to declining revenues and profitability over the years.

Should I buy, sell or hold Link Pharma Chem?

Which are the latest news on Link Pharma Chem?

Why is Link Pharma Chem falling/rising?

As of 04-Dec, Link Pharma Chem Ltd's stock is rising by 0.28% after two days of decline, indicating a potential trend reversal. However, it remains below its moving averages and has seen a 25.38% drop in delivery volume, suggesting weak investor confidence despite the recent price increase.

As of 04-Dec, Link Pharma Chem Ltd's stock price is currently rising, with a change of 0.09 (0.28%) upward. This increase comes after the stock experienced two consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 0.49% today, which may contribute to the positive momentum.<BR><BR>However, it is important to note that despite the recent rise, Link Pharma Chem is trading lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests that the stock is still underperforming relative to its historical price trends.<BR><BR>Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 25.38% against the 5-day average. This decline in trading activity could indicate a lack of strong investor confidence, which may counterbalance the recent price increase.<BR><BR>Overall, while the stock is currently rising, the broader context of its performance, including lower trading volumes and its position relative to moving averages, suggests that the upward movement may not be strongly supported.